The experimental design of the present study was conceived to perform a deep proteomic analysis of the spinal cord from ALS-TDP-43 patients and FTLD-U patients (all of them in both groups without beta-amyloid, tau or alpha-synuclein inclusions) comparing them with post mortem tissue from the same region of non-neurodegenerative control donors, in order to deep in the tardopathies knowledge. This evidence concerns the gene MAPT and amyotrophic lateral sclerosis.